We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Stock Moves -1.01%: What You Should Know
Read MoreHide Full Article
The latest trading session saw Eli Lilly (LLY - Free Report) ending at $586.46, denoting a -1.01% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.43%. Meanwhile, the Dow experienced a drop of 0.32%, and the technology-dominated Nasdaq saw a decrease of 2.43%.
Heading into today, shares of the drugmaker had gained 7.71% over the past month, outpacing the Medical sector's loss of 3.82% and the S&P 500's loss of 1.55% in that time.
Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 2, 2023. The company's earnings per share (EPS) are projected to be -$0.11, reflecting a 105.56% decrease from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $8.88 billion, up 27.92% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.65 per share and a revenue of $33.49 billion, signifying shifts of -16.25% and +17.36%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Eli Lilly. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 32.41% fall in the Zacks Consensus EPS estimate. Eli Lilly presently features a Zacks Rank of #3 (Hold).
In the context of valuation, Eli Lilly is at present trading with a Forward P/E ratio of 89.12. This indicates a premium in contrast to its industry's Forward P/E of 14.98.
We can also see that LLY currently has a PEG ratio of 3.49. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.77 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 236, which puts it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Stock Moves -1.01%: What You Should Know
The latest trading session saw Eli Lilly (LLY - Free Report) ending at $586.46, denoting a -1.01% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.43%. Meanwhile, the Dow experienced a drop of 0.32%, and the technology-dominated Nasdaq saw a decrease of 2.43%.
Heading into today, shares of the drugmaker had gained 7.71% over the past month, outpacing the Medical sector's loss of 3.82% and the S&P 500's loss of 1.55% in that time.
Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 2, 2023. The company's earnings per share (EPS) are projected to be -$0.11, reflecting a 105.56% decrease from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $8.88 billion, up 27.92% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.65 per share and a revenue of $33.49 billion, signifying shifts of -16.25% and +17.36%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Eli Lilly. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 32.41% fall in the Zacks Consensus EPS estimate. Eli Lilly presently features a Zacks Rank of #3 (Hold).
In the context of valuation, Eli Lilly is at present trading with a Forward P/E ratio of 89.12. This indicates a premium in contrast to its industry's Forward P/E of 14.98.
We can also see that LLY currently has a PEG ratio of 3.49. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.77 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 236, which puts it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.